Department of Otolaryngology - Head and Neck Surgery, Manukau Superclinic, 901 Great South Road, Manukau City Centre, Auckland, 2104, New Zealand.
Computer and Mathematical Sciences, University of Stirling, Stirling, FK9 4LA, Scotland, UK.
Eur Arch Otorhinolaryngol. 2024 May;281(5):2743-2747. doi: 10.1007/s00405-024-08576-2. Epub 2024 Mar 4.
Upper respiratory tract complaints are common in the general population. A safe, non-pharmacologic treatment would be an attractive option for many patients either as an alternative to existing therapies, or as a complementary therapy. This study assessed the acceptability, safety and possible efficacy of a nasal airflow oscillation device in a group of people suffering chronic nasal congestion.
Subjects with a known history of nasal congestion, but without fixed anatomical obstruction, participated in a prospective clinical study. Efficacy was assessed using peak nasal inspiratory flow (NPIF) and a 10-point visual analogue scale (VAS) administered before and after the oscillation device had been worn for twenty minutes.
Twenty-one subjects (mean age 37 years; 43% female) were enrolled in the study. After treatment with the small nasal airflow oscillation device for twenty minutes, average NPIF increased significantly from 84.8 L/minute to 99.0 L/minute (p < 0.05). There was a corresponding significant reduction in the VAS score for nasal congestion (p < 0.05). Similar significant improvements were also seen for the immediate sensation of nasal drainage, sinonasal pressure and overall sinonasal symptoms (p < 0.05). There was no change in the sense of smell (p = 0.37). Subjects rated ease of use highly; average = 9.1 (Range 7-10).
Treatment of nasal congestion with the nasal airflow oscillation device was found to result in significant improvement in NPIF after twenty minutes of use. Initial patient-reported outcomes improved significantly, and the treatment was safe and highly acceptable.
Public clinical trial registration: Universal Trial Number (U1111-1259-0704). Australian New Zealand clinical trials registration: ACTRN12623001307695.
上呼吸道症状在普通人群中很常见。对于许多患者来说，一种安全的、非药物治疗方法将是一种有吸引力的选择，无论是作为现有治疗方法的替代方法，还是作为补充治疗方法。本研究评估了一种鼻腔气流振荡装置在一组患有慢性鼻塞的人群中的可接受性、安全性和可能的疗效。
有已知鼻塞病史但无固定解剖结构阻塞的受试者参加了一项前瞻性临床研究。使用峰流速仪（NPIF）和 10 分制视觉模拟量表（VAS）在佩戴振荡装置 20 分钟前后进行评估。
21 名受试者（平均年龄 37 岁；43%为女性）参加了研究。使用小型鼻腔气流振荡装置治疗 20 分钟后，平均 NPIF 从 84.8 L/min 显著增加到 99.0 L/min（p < 0.05）。鼻塞的 VAS 评分也有相应的显著降低（p < 0.05）。鼻腔引流、鼻-鼻窦压力和整体鼻-鼻窦症状的即时感觉也有类似的显著改善（p < 0.05）。嗅觉无变化（p = 0.37）。受试者对使用的易用性评价很高，平均评分为 9.1（7-10 分）。
使用鼻腔气流振荡装置治疗鼻塞 20 分钟后，NPIF 显著改善。初始患者报告的结果显著改善，治疗安全且高度可接受。
公共临床试验注册：通用试验编号（U1111-1259-0704）。澳大利亚新西兰临床试验注册：ACTRN12623001307695。
